![Taysha Gene Therapies, Inc. logo](/logos/TSHA.webp)
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Overview | Financials
Company Name | Taysha Gene Therapies, Inc. |
Symbol | TSHA |
Currency | USD |
Price | 2.04 |
Market Cap | 418,083,720 |
Dividend Yield | 0% |
52-week-range | 1.27 - 4.32 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sean P. Nolan |
Website | https://www.tayshagtx.com |
An error occurred while fetching data.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD